Biotechs’ Size A Competitive Advantage Over Big Pharma In Compliance Arena – BIO Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
Smaller biotechs should view current regulatory environment as a way to leverage size to better compete with larger companies, Cubist exec says.